PTC Therapeutics Inc
(STU:BH3)
€
68.32
-2.96 (-4.15%)
Market Cap: 5.68 Bil
Enterprise Value: 4.37 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 52/100 PTC Therapeutics Inc at Citi Global Healthcare Conference Transcript
Dec 04, 2025 / 03:30PM GMT
Release Date Price:
€63.5
(-3.79%)
Geoffrey Meacham;Douala Branch;Analyst
Citibank Cameroon SA
()-
Conference, my name's Geoff Meacham. I'm the senior biopharma analyst here, and I have Jarway Fang from my team on here as well. We're thrilled today to have PTC Therapeutics. With us on stage is Matt Klein, CEO. Matt, welcome.
Matthew Klein
PTC Therapeutics Inc - Chief Executive Officer, Director
Good to see you. Great to be here.
Geoffrey Meacham;Douala Branch;Analyst
Citibank Cameroon SA
()-
So, lots of questions on Safiance and on your R&D day, but maybe just for those on the webcast, just give us, a bit of a quick background or overall, and then we can get right into it.
Matthew Klein
PTC Therapeutics Inc - Chief Executive Officer, Director
Yeah, absolutely. So PTC is a global biopharmaceutical company. We are focused on rare diseases and other disorders of high unmet need. We have a robust, commercial portfolio with 6 products that
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot